Evidence map›Paper›PMID 35406592›Full record

ArticleCancers2022

Folic Acid Treatment Directly Influences the Genetic and Epigenetic Regulation along with the Associated Cellular Maintenance Processes of HT-29 and SW480 Colorectal Cancer Cell Lines.

Sára Zsigrai, Alexandra Kalmár, Barbara K Barták, Zsófia B Nagy, Krisztina A Szigeti, Gábor Valcz, William Kothalawala, Titanilla Dankó, Anna Sebestyén, Gábor Barna and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Sára ZsigraiDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Alexandra KalmárDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Barbara K BartákDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Zsófia B NagyDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Krisztina A SzigetiDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Gábor ValczDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
William KothalawalaDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Titanilla Dankó1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Anna Sebestyén1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-8814-4794
Gábor Barna1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-8895-3062
Orsolya PipekDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, 1117 Budapest, Hungary.
István CsabaiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, 1117 Budapest, Hungary.
Zsolt TulassayMolecular Medicine Research Group, Eötvös Loránd Research Network, 1083 Budapest, Hungary.
Péter IgazDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.ORCID 0000-0003-2192-554X
István TakácsDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.ORCID 0000-0002-7810-4833
Béla MolnárDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.
Semmelweis University · HUEötvös Loránd University · HU

Funding

HIGHER EDUCATION INSTITUTIONAL EXCELLENCE PROGRAM OF THE MINISTRY OF HUMAN CAPACITIES IN HUNGARYNATIONAL RESEARCH, DEVELOPMENT AND INNOVATION OFFICE, HUNGARY 2020-1.1.2-PIACI-KFI-2021-00298NATIONAL RESEARCH, DEVELOPMENT AND INNOVATION OFFICE, HUNGARY FIEK_16-1-2016-0005NEW NATIONAL EXCELLENCE PROGRAM OF THE MINISTRY FOR INNOVATION AND TECHNOLOGY FROM THE SOURCE OF THE NATIONAL RESEARCH, DEVELOPMENT AND INNOVATION FUND ÚNKP-21-4-I-SE-20
6 · The paper itself

Abstract

Folic acid (FA) is a synthetic form of vitamin B9, generally used as a nutritional supplement and an adjunctive medication in cancer therapy. FA is involved in genetic and epigenetic regulation; therefore, it has a dual modulatory role in established neoplasms. We aimed to investigate the effect of short-term (72 h) FA supplementation on colorectal cancer; hence, HT-29 and SW480 cells were exposed to different FA concentrations (0, 100, 10,000 ng/mL). HT-29 cell proliferation and viability levels elevated after 100 ng/mL but decreased for 10,000 ng/mL FA. Additionally, a significant (

Indexed as

colorectal cancerDNA methylationfolic acidgene expressiongenomic stability

Identifiers

PMID35406592
PMCPMC8997840
OpenAlexW4223522740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.